| Literature DB >> 31632110 |
Francesco Francini-Pesenti1, Paolo Spinella1, Lorenzo A Calò2.
Abstract
Metabolic syndrome (MetS) is a set of cardiovascular risk factors which severely increases the risk of type II diabetes, renal disease and cardiovascular disease. Over the last decades, the role of dietary bioactive substances in features of MetS has been extensively investigated. Due to their multiple properties, these plant-derived natural compounds have demonstrated to provide positive effects in obesity, diabetes, renal and in cardiovascular disease. Catechins of green tea and caffeine reduce body mass index and waist circumference. Catechins, anthocyanins and proanthocyanidins of cocoa reduce blood pressure and blood glucose. Curcumin and silymarin exert hepatoprotective effects. Monacolins of red yeast rice are effective cholesterol-lowering agents. However, inconsistent or conflicting results have been found in clinical trials when other promising compounds in vitro or in animal studies, such as policosanol, curcumin or silymarin, were used. Low oral bioavailability of substances, ineffective dosages, inadequate treatment duration and insufficient statistical approach may explain the lack of effectiveness observed in some human studies. Further clinical studies are needed to better understand the role of bioactive compounds in the prevention and management of MetS.Entities:
Keywords: bioactive substances; cardiovascular risk; metabolic syndrome; nutrition
Year: 2019 PMID: 31632110 PMCID: PMC6778731 DOI: 10.2147/DMSO.S214550
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Definitions of metabolic syndrome
| WHO 1999 | IGT or DM, and/or IR, together with two or more of the following criteria:
HDL-cholesterol <0.9 mmol/L (35 mg/dL) in men, <1.0 mmol/L (40 mg/dL) in women Triglycerides >1.7 mmol/L (150 mg/dL) Waist/hip ratio >0.9 (men) or >0.85 (women) or BMI > 30 kg/m Blood pressure >140/90 mmHg |
| NCEP ATP III 2001 | Three or more of the following criteria:
Blood glucose greater than 5.6 mmol/L (100 mg/dL) or drug treatment for elevated blood glucose HDL-cholesterol <1.0 mmol/L (40 mg/dL) in men, <1.3 mmol/L (50 mg/dL) in women or drug treatment for low HDL-C Blood triglycerides >1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides Waist >102 cm (men) or >88 cm (women) Blood pressure >130/85 mmHg or drug treatment for hypertension |
| AHA/NHLBI 2004 | Three or more of the following criteria:
Waist circumference >102 cm in men and >88 cm in women Blood pressure ≥130/≥85 mmHg or specific medication Triglyceride plasma level ≥150 mg/dL (1.7 mmol/L) HDL-cholesterol <40 mg/dL (1.03 mmol/L) in men and <50 mg/dL (1.29 mmol/L) in women Fasting plasma glucose ≥100 mg/dL (5.6 mmol/L) or history of diabetes mellitus or taking antidiabetic medications |
| IDF 2005 |
Abbreviations: AHA/NHLBI, American Heart Association/National Heart, Lung, and Blood Institute; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; IGT impaired glucose tolerance; IR, insulin resistance; NCEP ATP III, Cholesterol Education Program Adult Treatment Panel III.
Phytochemicals and metabolic syndrome: clinical trials
| Aim | Treatment | Result | Reference |
|---|---|---|---|
| To evaluate the effect of catechins on body fat reduction | Oolong tea with green tea extract (690 mg catechins daily) or oolong tea containing (22 mg catechins daily) for 12 weeks | BW, BMI, waist circumference, body fat mass and subcutaneous fat area were significantly lower in the green tea extract group than in the control group | |
| To compare the effects of supplementation of green tea on BW, blood glucose and lipid profile, and oxidative stress in obese subjects with MetS | Green tea (4 cups daily), or green tea extract (2 capsules and 4 cups water/d) for 8 weeks | Green tea beverage consumption or extract supplementation significantly decreased BW and BMI. Green tea beverage lowered lipid peroxidation versus controls | |
| To evaluate the effects of green tea extract on the lipid profile, blood glucose and antioxidant status of obese patients | 379 mg of green tea extract (EGCG 208 mg) daily for 3 months | Green tea extract supplementation induced the reduction of BMI, waist circumference, TC, LDL-C, TG, and increased the total antioxidant level | |
| To investigate the effect of dietary supplementation with EGCG on IR and associated metabolic risk factors in man | 400 mg capsules of EGCG twice daily for 8 weeks | EGCG treatment had no effect on insulin sensitivity, IR or glucose tolerance but reduced diastolic BP | |
| To investigate the effect of a green tea–caffeine mixture on BW maintenance after BW loss in moderately obese subjects | Green tea–caffeine mixture (EGCG 270 mg +150 mg caffeine per day) or placebo. | High caffeine intake was associated with BW loss. In habitual low caffeine consumers, the green tea–caffeine mixture improved BW maintenance, partly through thermogenesis and fat oxidation | |
| To evaluate the freeze-dried strawberry supplementation in improving BP, plasma glucose level, and dyslipidemia in obese subjects with MetS | 4 cups of freeze-dried strawberry beverage (50 g freeze-dried strawberries approximately 3 cups fresh strawberries) daily for 8 weeks | Strawberry supplementation significantly decreased TC and LDL-C, small low-density lipoprotein particles, and circulating levels of vascular cell adhesion molecule. Serum glucose, TG, HDL-C, BP and waist circumference were not affected | |
| To investigate the apple and blackcurrant polyphenol-rich drinks in reducing postprandial blood glucose, insulin, C-peptide and GIP concentration | 2 polyphenol-rich drinks | Polyphenol-rich drinks significantly decreased postprandial blood glucose, insulin, C-peptide and GIP | |
| To determine the modulation of lipid and glucose metabolism, oxidative stress and inflammation, by an açaí beverage | 25 mL twice per day of a placebo control or açaí beverage (1139 mg/L gallic acid equivalents of total polyphenolics) for 12 weeks | Plasma level of interferon gamma and urinary level of 8-isoprostane, were significantly decreased after 12 weeks of açaí consumption compared to the placebo control. No significant modification of biomarkers for lipid and glucose metabolism was observed | |
| To evaluate the acute effects of solid dark chocolate and liquid cocoa intake on endothelial function and BP in overweight adults | In phase 1: solid dark chocolate bar (containing 22 g cocoa powder) or a cocoa-free placebo bar. In phase 2: sugar-free cocoa (containing 22 g cocoa powder), sugared cocoa (containing 22 g cocoa powder) or a placebo | Solid dark chocolate and liquid cocoa ingestion improved endothelial function (measured as flow-mediated dilatation). BP decreased after the ingestion of dark chocolate and sugar-free cocoa compared with placebo | |
| To compare the effects of either dark or white chocolate bars on BP and glucose and insulin responses to an oral-glucose-tolerance test in healthy subjects | 100 g dark chocolate bars, which contained approximately 500 mg polyphenols, or 90 g white chocolate bars for 15 days | HOMA-IR was significantly lower and QUICKI was significantly higher after dark than after white chocolate ingestion. Systolic BP was lower after dark than after white chocolate ingestion | |
| To evaluate the effects of 3-month treatment with epicatechin-rich cocoa in oxidative stress. | 18 g of natural cocoa powder (100 mg epicatechin) daily for 3 months | Treatment with with epicatechin-rich cocoa increased the glutathione levels and decreased the nitrotyrosilation and carbonylation of proteins | |
| To examine the effects of chocolate on lipid profiles, weight and glycemic control in individuals with type 2 diabetes | 45 g chocolate with or without a high polyphenol content for 8 weeks | HDL-C increased significantly with high polyphenol chocolate with a decrease in the TC:HDL-C ratio. No changes were seen in BW nor in glycemic control | |
| To evaluate the effect of a curcumin extract for 12 weeks on BW, blood glucose, and lipid profiles in patients with MetS | Turmeric extract capsule (630 mg of curcumin) thrice daily | HDL-C and TG significantly increased and the LDL-C significantly reduced after 12 weeks of treatment. BW and glucose homeostasis did not improve | |
| To evaluated the effect of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in type 2 diabetes patients | Curcuminoids 500 mg/day co-administered with piperine (5 mg/day) or placebo for 3 months | Significant reduction in serum levels of blood glucose, HbA1c, C-peptide and transaminases in curcuminoids compared with the placebo group | |
| To test the effect of phosphatidylserine- and piperine-containing curcumin phytosomes on metabolic parameters related to IR | Phytosomal curcumin (curcumin 200 mg, phosphatidylserine 120 mg, phosphatidylcholine 480 mg and piperine 8 mg) for 8 weeks | In the curcumin group fasting plasma insulin, HOMA-IR, BW, TG, HDL-C, liver transaminases, gamma-GT, index of liver steatosis and serum cortisol improved compared to the baseline. Fasting plasma insulin, TG, liver transaminases, fatty liver index and serum cortisol level also significantly improved compared with the placebo-treated group | |
Abbreviations: BMI, body mass index; BP, blood pressure; BW, body weight; EGCG, epigallocatechin gallate; GIP, gastrointestinal peptide; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment insulin resistance; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
Effects of plant substances on the components of metabolic syndrome and associated conditions
| Components | Plants/substances | Mechanisms | References |
|---|---|---|---|
| Abdominal obesity | Caffeine | Adrenergic stimulation | |
| Tea (catechins) | Adrenergic stimulation | ||
| Impaired glucose tolerance | Berries (anthocyanins, flavonoids, stilbenes) | Slowing carbohydrate digestion and absorption; stimulating insulin secretion via AMPK pathway; decreasing cell oxidative damage | |
| Pomegranate (ellagitannins, anthocyanins) | Inhibition of α-glucosidase; increasing glucose transporter type 4 activity | ||
| Hypertriglyceridemia | Olive oil | Increasing VLDL catabolism | |
| Low levels of HDL-C | Curcuma (curcumin)? | -Improvement of HDL metabolism | |
| High blood pressure | Cocoa (catechins, proanthocyanidins, flavonols) | Activation of endothelial NO synthase; inhibition of angiotensin-converting enzyme | |
| Fatty liver | Curcuma (curcumin) | Antioxidant and antiinflammatory effects; inhibition of fibrogenesis | |
| Chronic inflammation | Tea, catechins | Modulation signaling of inflammatory response pathways, antioxidant activity | |
| LDL-C/small LDL | Tea, catechins | Reduction of lipid intestinal absorption, upregulation of LDL receptors; protection of lipid from oxidative damage |
Abbreviations: AMPK, 5ʹ adenosine monophosphate kinase; COX, cyclooxygenase; HDL-C, high-density lipoprotein cholesterol; IR, insulin resistance; LOS, lipooxygenase; MUFAs, monounsaturated fatty acids; NAFLD, nonalcoholic fatty liver disease; NF-kB, nuclear factor kB; NO, nitric oxide; TNFα, tumor necrosis factor alpha; VLDL, very low-density lipoprotein.
Figure 1Effect of natural bioactive compounds on the main features of MetS.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; cAMP, cyclic adenosine monophosphate; COMT, catechol-O-methyl transferase enzyme; EGCG, epigallocatechin gallate; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment insulin resistance; IR, insulin resistance; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; NAFLD, non alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NF-kB, nuclear factor kB; PAI-1, plasminogen activator inhibitor-1; PC, policosanol; TG, triglycerides; TNFα, tumor necrosis factor alpha.